CRISPR Therapeutics AG CRSP reported new topline study results on Wednesday to establish risk factors for atherosclerotic heart disease.The company disclosed data regarding the first 10 patients across its Phase 1 first-in-human dose escalation trial, targeting ANGPTL3 in four patient groups with elevated low-density lipoprotein (LDL), triglyceride (TG), or both.The data comes from the first 10 patients across the first four cohorts (lean body weight-based doses of DL1 [0.1 mg/kg], DL2[0.3 mg/kg], DL3 [0.6 ...

CRISPR Therapeutics (CRSP) reported first-quarter 2025 loss of $1.58 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.27 per share. In the year-ago period, the company had recorded a loss of $1.43 per share. Total revenues, comprising only grant revenues, amounted to $0.86 million in the quarter, which significantly missed the Zacks Consensus Estimate of $5 million. In the year-ago period, the company recorded total revenues of $0.5 million, which also comprised grant revenues. S ...

产品获批与合作情况 - 2023年CASGEVY成为全球首个获批的基于CRISPR的基因编辑疗法，已在美国、欧盟等多地获批用于治疗12岁及以上SCD或TDT患者[101] - 公司与Vertex合作开发和商业化CASGEVY，还在进行多项临床试验，包括针对不同年龄段患者的试验和长达15年的长期随访试验[101] - 2015年公司与Vertex就血红蛋白病和囊性纤维化项目合作，2017年Vertex行使共同开发和商业化血红蛋白病项目的选择权[114] - 2018 - 2023年公司与ViaCyte合作糖尿病项目，2023年ViaCyte选择退出，公司继续推进CTX211项目[115] - 2023年公司与Vertex签订非独家许可协议，至今已确认2.05亿美元的前期和里程碑付款收入[115] 在研项目进展 - CTX112和CTX131是公司推进的下一代同种异体CAR T项目，分别靶向CD19和CD70，正在进行多项临床试验评估其安全性和有效性[104][105][106] - 公司的体内基因编辑项目CTX310和CTX320分别针对心血管疾病的ANGPTL3和Lp(a)靶点，正在进行临床试验[109] - 公司为治疗T1D开发基因编辑干细胞衍生疗法，有CTX211、CTX213等项目，还向Vertex授予非独家许可[111] 公司融资情况 - 公司自2013年10月成立以来主要致力于研发，主要通过私募优先股、发行普通股、可转换贷款和合作协议收入来融资[117] - 2025年第一季度，公司根据2021年ATM发行并出售0.2万股普通股，总收益870万美元[138] - 截至2025年3月31日，公司当前招股说明书补充文件下剩余普通股总收益可达3.548亿美元，已发行并出售210万股，总收益2.419亿美元[139] - 2024年2月，公司通过注册直接发行向机构投资者出售约2.8亿美元普通股，净收益2.79亿美元[140] - 2024年3月31日结束的三个月，通过向机构投资者出售普通股获得约2.8亿美元收益，净收益2.79亿美元[149] 财务数据关键指标变化 - 截至2025年3月31日和2024年的三个月，公司确认的收入不重要，预计短期内不会从自有产品销售中获得收入[120] - 2025年第一季度总营收86.5万美元，较2024年同期的50.4万美元增加36.1万美元[130] - 2025年第一季度研发费用7248.4万美元，较2024年同期的7617.2万美元减少368.8万美元，主要因员工相关费用减少[130][132] - 2025年第一季度行政费用1929.6万美元，较2024年同期的1795.3万美元增加134.3万美元，主要因股份支付费用增加[130][133] - 2025年第一季度合作费用净额5750.9万美元，较2024年同期的4696.6万美元增加1054.3万美元，主要因商品销售成本和其他商业成本增加[130][134] - 2025年第一季度其他收入净额1353.7万美元，较2024年同期的2472万美元减少1118.3万美元，主要因公司股权证券公允价值变动和利息收入减少[130][135] - 截至2025年3月31日，公司现金、现金等价物和有价证券为18.553亿美元，累计亏损15.019亿美元[136] - 2025年3月31日结束的三个月，经营活动净现金使用为5390万美元，2024年同期为提供1.098亿美元，增加1.637亿美元[146] - 2025年3月31日结束的三个月，投资活动净现金使用为1980万美元，2024年同期为9780万美元，减少7804.5万美元[148] - 2025年3月31日结束的三个月，融资活动净现金提供为1060万美元，2024年同期为3.059亿美元，减少2.95346亿美元[149] - 2025年第一季度净亏损1.36亿美元，2024年第一季度净亏损1.166亿美元，增加1940万美元[146] - 2024年第一季度从Vertex收到应收款2亿美元，2025年第一季度为2500万美元[146] - 截至2025年3月31日，公司有现金、现金等价物和有价证券18.553亿美元[155] 公司运营资金预期 - 基于研发计划和项目进展预期，公司现有现金、现金等价物和有价证券预计至少可支持未来24个月的运营费用和资本支出[143] 风险因素 - 若利率增减1%，投资组合公允价值变动 immaterial amount [155] - 公司面临瑞士法郎和英镑兑美元汇率波动风险，目前外汇交易损益对财务报表无重大影响[156] - 通胀增加公司劳动力、临床试验和制造成本，但2025年和2024年3月31日结束的三个月对业务、财务状况和经营成果无重大影响[157]

Exhibit 99.1 CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3 -Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low- density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation anticipated at a medical meeting in the second half of 2025- -CASGEVY® continues to gain mom ...

-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low- density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation anticipated at a medical meeting in the second half of 2025- -CASGEVY® continues to gain momentum; more than 65 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 90 patients have had cells collected across all regions; new patient in ...

基因治疗行业表现 - 基因治疗公司CRISPR Therapeutics (CRSP)和Intellia Therapeutics (NTLA)在2025年第一季度股价波动剧烈 截至统计时CRSP年内股价下跌282% NTLA下跌2419% [1] 分析师背景 - 分析师拥有生物学背景 生物医学硕士和生物工程博士学位 在细胞与基因治疗(CGT)领域有20年以上研发经验 专注于评估新型疗法(包括CGT)的投资潜力 [1] - 分析师关注领域包括生物技术 制药 医疗技术和医疗保健类股票 [1] 社交媒体信息 - 分析师在BlueSky平台的账号为biocgtinvestorbskysocial [1] 注 原文中doc id=2和doc id=3的内容为披露声明和免责条款 根据任务要求不予总结

Iovance Biotherapeutics (IOVA -1.52%) and CRISPR Therapeutics (CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have significantly lagged the market over the past three years due to a combination of factors.However, these groundbreaking companies are still looking at meaningful opportunities and catalysts that could help turn things around in the long run -- and perhaps even deliver life-changing returns. Here's why Iovance Biothe ...

In the latest market close, CRISPR Therapeutics AG (CRSP) reached $39.11, with a +1.48% movement compared to the previous day. This move lagged the S&P 500's daily gain of 2.03%. At the same time, the Dow added 1.23%, and the tech-heavy Nasdaq gained 2.74%.The company's stock has dropped by 1.63% in the past month, exceeding the Medical sector's loss of 8.57% and the S&P 500's loss of 5.07%.The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its u ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $38.54, marking a -1.76% move from the previous day. This change lagged the S&P 500's daily gain of 1.67%. Elsewhere, the Dow saw an upswing of 1.07%, while the tech-heavy Nasdaq appreciated by 2.5%.Coming into today, shares of the company had lost 4.06% in the past month. In that same time, the Medical sector lost 9.34%, while the S&P 500 lost 6.57%.Market participants will be closely following the financial results of CRISPR Therapeuti ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.Of course, it wouldn't be wise to rush to invest in these companies for that reason alone, but it might be worth looking deeper into what the Street considers severely undervalued drugmakers. Read on to learn m ...